Reading WST? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track WST free→
WST
West Pharmaceutical ServicesNYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-06-12
Intact
$328.82-0.46%
Close 2026-06-12 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality is mixed, and risk is moderate, while the sector backdrop is a headwind. Peer multiples imply a price about 92% below where it trades (it looks expensive on this basis); the read is rich, as it trades above peer multiples, and the longer horizon does not make that back through growth. Key factors to watch include guidance changes and sector trends, particularly the performance of sector bellwethers. This read is provisional.
as of 2026-06-12
Quick facts
- Exchange
- NYSE
- Sector
- Health Care
- Industry
- Medical Instruments & Supplies
- Market cap
- $23.34B
- Employees
- —
- IPO date
- 1994-05-13
- Next earnings
- —
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 8 valuation methods, at three horizons. Current price $328.82. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryexpensive
$169.97consensus
Range $166.09 – $203.32
vs price: +93% above
Method agreement — · 8 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearexpensive
$236.25consensus
Range $213.32 – $333.09
vs price: +39% above
Method agreement — · 6 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearfull
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Durable premiumlow confidence
At $329 the market pays 41× p/e — above the 20× p/e peer median but in line with its own 40× history. That premium reflects a durable franchise our peer-anchored $171 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $265–$400. Not investment advice.
Multiple (P/E)
41.5x
peer 20.0x · own history 40.3x
Premium
2.1x peer
1.0x its own history
Growth the price needs
93%
our forecast 10%
Our fair value
$170.67
range $166.09 – $201.35
Analyst range(a guide on our number, not a target)Our number is below the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
expensiverich12-month view
What's priced inUnjustified
The market is pricing in roughly 93% near-term growth, well above our forecast of about 10%. This describes what's priced in, not a forecast of the move.
High fragilityrisk posture, not a price call
Flags: expensive valuation, weak execution quality, a turbulent sector regime (Heating).
Historical context
For similar setups historically (n=889): about 49% saw a 20%+ drawdown, and roughly 85% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
91st pctl · Health Care
Earnings quality
neutralOver the trailing year it converted 1.32x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
42nd pctl · Health Care
Macro sensitivity
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
Management & capital allocation
volatile10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Bullish11 analysts, 82% Buyfor period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $2.08 → $2.08 (-0.2% / 30d). 0 raised, 1 cut, 11 covering analysts.
Rating actions
1 upgrade, 0 downgrades / 30d, 2 maintained. 82% of analysts rate Buy.
Price target activity
1 PT revisions / 30d. Avg target 25.1% above current price.
Material events
0 positive, 0 negative / 30d.
Transition story with positive analyst positioning (often a turnaround setup).
Sector context
Intermediate · WeeklyManagement scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: strong
- Capital allocation
- strong
- Earnings discipline
- strong
- Margin discipline
- strong
- Balance sheet
- strong
- Post-call reaction
- weak
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$117.
How much price usually moves either way.
On a bad day, this stock has moved -$319.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,470.
Deepest peak-to-trough drop in the last year.
moderateas of 2026-06-12
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideHigh confidenceMonthsactive 18d
Watch for Q2 2026 net sales guidance between $830M and $850M
Why it matters: This range indicates continued growth momentum. It will show if demand remains strong.
What confirms / what disproves
Confirms:Q2 2026 net sales reported within the range of $830 million to $850 million.
Disproves:Q2 2026 net sales fall below $830 million.
Earnings call
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for WST yet.
This sector is also watching
- Watch for Health Care revenue growth dropping below 8% YoY
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like ISRG, MDLN, and BDX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting WST and other Healthcare names. Worth watching these names for early signals.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for WST and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
- If WST beats again next quarter like it did this past one (a big beat of +27% on the 2026-03-31 print), the momentum tends to extend, with Street estimates ratcheting up and the stock typically following.
Downside triggers
- If WST reverses and cuts guidance after recently raising (RAISED as of 2026-04-23), that's the worst kind of move: a credibility hit on top of the lower number. Stocks usually get punished disproportionately for this.
- If sector bellwethers like ISRG, MDLN, and BDX start missing or guiding lower, the Healthcare tailwind helping WST and other Healthcare names could fade. Watch these names for early warning.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-06-0112d agoItem 5.02
President and Chief Executive Officer — Eric M. Green: Mr. Eric M. Green is retiring and being succeeded by Michel Lagarde.
Executive changeneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+10 vs last weeklatest as of 2026-06-13
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.